Taro Inaba
Direttore/Membro del Consiglio presso Actimis Pharmaceuticals, Inc.
Profilo
Taro Inaba is currently a Director at Actimis Pharmaceuticals, Inc., Boston Biomedical, Inc., OMEICOS Therapeutics GmbH, and Inflectis Bioscience SAS.
In the past, he was the President & CEO of Mitsui & Co. Global Investment, Inc. and held director positions at Sopogy, Inc., CanBas Co., Ltd., Anaeropharma Science, Inc., Hutchison MediPharma Ltd., BioAmber, Inc., NapaJen Pharma, Inc., and Mitsui & Co. Global Investment Ltd.
He earned an MBA from European University Portugal Centro de Estudos de Gestão SA and an undergraduate degree from Kyoto University.
Posizioni attive di Taro Inaba
Società | Posizione | Inizio |
---|---|---|
Actimis Pharmaceuticals, Inc.
Actimis Pharmaceuticals, Inc. BiotechnologyHealth Technology Actimis Pharmaceuticals, Inc. provides pharmaceutical research and development services. it focuses on the development of small therapeutics for respiratory and inflammatory disorders. The company was founded by Kevin B. Bacon in November 2004 and is headquartered in San Diego, CA. | Direttore/Membro del Consiglio | - |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Direttore/Membro del Consiglio | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Direttore/Membro del Consiglio | - |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Taro Inaba
Società | Posizione | Fine |
---|---|---|
Sopogy, Inc.
Sopogy, Inc. SemiconductorsElectronic Technology Sopogy Inc. designs, manufactures, and markets micro-scaled concentrating solar power technology (MicroCSP); and sells related software, and services. Their products include SopoFlare, SopoNova, SopoHelios, SopoLite, and the SopoSoft operating system. Sopogy's MicroCSP technologies are used to create process heat, solar air conditioning or electrical power and can be ground or rooftop mounted. The company was founded in 2002 by Darren T. Kimura and is headquartered in Honolulu, HI. | Direttore/Membro del Consiglio | - |
BIOAMBER INC. | Direttore/Membro del Consiglio | - |
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Direttore/Membro del Consiglio | - |
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Direttore/Membro del Consiglio | - |
CANBAS CO., LTD. | Direttore/Membro del Consiglio | - |
Formazione di Taro Inaba
Kyoto University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
CANBAS CO., LTD. | Health Technology |
Aziende private | 12 |
---|---|
Actimis Pharmaceuticals, Inc.
Actimis Pharmaceuticals, Inc. BiotechnologyHealth Technology Actimis Pharmaceuticals, Inc. provides pharmaceutical research and development services. it focuses on the development of small therapeutics for respiratory and inflammatory disorders. The company was founded by Kevin B. Bacon in November 2004 and is headquartered in San Diego, CA. | Health Technology |
Sopogy, Inc.
Sopogy, Inc. SemiconductorsElectronic Technology Sopogy Inc. designs, manufactures, and markets micro-scaled concentrating solar power technology (MicroCSP); and sells related software, and services. Their products include SopoFlare, SopoNova, SopoHelios, SopoLite, and the SopoSoft operating system. Sopogy's MicroCSP technologies are used to create process heat, solar air conditioning or electrical power and can be ground or rooftop mounted. The company was founded in 2002 by Darren T. Kimura and is headquartered in Honolulu, HI. | Electronic Technology |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
Mitsui & Co. Global Investment, Inc.
Mitsui & Co. Global Investment, Inc. Investment ManagersFinance Mitsui & Co. Global Investment, Inc. (Mitsui & Co. Global Investment) is a venture capital subsidiary of Mitsui Ventures founded in 1999. The firm is headquartered in Menlo Park, California. | Finance |
Mitsui & Co. Global Investment Ltd.
Mitsui & Co. Global Investment Ltd. Investment ManagersFinance Mitsui & Co. Global Investment Ltd is a private Equity/venture Capital firm, a subsidiary of Mitsui & Co., Ltd. founded in 1996. The firm is headquartered in Tokyo. | Finance |
European University Portugal Centro de Estudos de Gestão SA | Consumer Services |
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
BioAmber, Inc.
BioAmber, Inc. Chemicals: SpecialtyProcess Industries BioAmber, Inc. is an industrial biotechnology company, which produces sustainable chemicals. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in everyday products, including plastics, resins, paints, food additives and personal care products. The firm's products include bio-based succinic acid, butanediol and bio-based disodium succinate. The company was founded on October 15, 2008 and is headquartered in Montreal, Canada. | Process Industries |
NapaJen Pharma, Inc.
NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Health Technology |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | Health Technology |
- Borsa valori
- Insiders
- Taro Inaba